East Sunshine Drug: $1.626 billion, Acquisition of Large-Volume Generics

original title: East Sunshine Medicine: 1.626 billion, the acquisition of large-volume generic drugs
East Sunshine group layout is deep, in the field of medicine and health accumulation gradually cashed inYichang Dong Sunshine Yangtze Pharmaceutical Co., Ltd("East Sunshine Pharmaceuticals") recentlyto enrich the product range, enhance its market competitiveness, after considering the potential market and long-term development strategy of the target product, after considering the potential market and long-term development strategy of the target product, after friendly consultation between the two sides of the transaction, it is proposed to evaluate the price of RMB162,643.46 million by Guangdong Dongsun Pharmaceutical Co., Ltd("Guangdong Dongsun Pharmaceutical") to develop the following 27 products (hereinafter referred to as "Target Products" of the relevant intellectual property rights) of all the relevant intellectual property rights in ChinaIf laws and regulations and policy reasons, Dongsun medicine can not directly hold the above-mentioned production approval, by the East Sunshine Drug control of eligible subsidiaries to be granted the above 27 products production approval ownershipCan pay attention to some of the varieties that have been valued over 100 million! In vitro transition to the bodyThis is not the first timeGuangdong Dongsun Pharmaceuticals is a controlling subsidiary of Shenzhen Dongsun Industrial, the controlling shareholder of the company, and is a related party to the companymain financial data as of December 31, 2017: total assets of RMB296,226.17 million, total liabilities of RMB253,027.03 million, net assets of RMB43,199.14 million, operating income as of December 2017 was RMB105,939.43 million, total profit of RMB7,990.81 million, net profit of RMB7,990.81 million, net profit of RMB7,990.81 million, net profit of RMB96.66.66.66.06.66.06.66.66.66.66.66.66.66.66.66.66.66.66.69 millionthe transaction price and settlement method
after friendly consultation between the two sides, the total amount of the transaction was determined to be RMB162,643.46 millionthe specific payment method is as follows:1, advance payment for the evaluation report assessed the product price of 50% of the total, that is, 81,321.73 million yuan, from the effective date of this agreement within 30 working days, by the East Sunshine Pharmaceuticals one-time payment to Guangdong Dongsun Pharmaceutical2, milestone payment is 20% of the total evaluation price of the product assessed in the Assessment Report, and within 30 working days from the date of each product obtaining the relevant approval of the State Drug Administration and the approval changed to all of the relevant approval of Dongsun Pharmaceutical soning or its holding subsidiary, the milestone payment shall be paid at 20% of the corresponding product evaluation price, and the 27 target products will be paid for a total of RMB 32,528.69 million3The final payment is 30% of the evaluation price of the product assessed in the Assessment Report and paid in two instalments:(1) When the total sales revenue generated by the above 27 products reaches RMB 500 million (excluding VAT) or more in a fiscal year for the first time, Dongsun medicine shall, within 30 working days from the date of the issuance of the relevant audit report in the fiscal year, has obtained the relevant approval of the State Drug Administration and the approval of this document Changed to a single product owned by Dongsun Pharmaceutical sits or its controlling subsidiaries, to pay one-third of the 30% of the assessed price of the product to Guangdong Dongsun Pharmaceuticals, and(2) after reaching the aforementioned total sales target, when the total sales revenue generated by 27 products reaches RMB 1 billion (excluding VAT) or more for the first time in one fiscal year, Andanyn Pharmaceuticals shall, within 30 working days from the date of the issuance of the relevant audit report in that fiscal year, In respect of the approval of the State Drug Administration and the approval changed to a single product owned by Dongsun Pharmaceutical scou or its holding subsidiary, two-thirds of the evaluation price of the product was paid to Guangdong Dongsun Pharmaceuticals, and 27 target products amounted to RMB 48,793.04 millionreferences:NMPA/CDE;, Pharnex Datamonitor; Pharmaceutical sephora
FDA/EMA; public disclosure byrelated companies;, etc